Due: June 17, 2026
The purpose of this Request for Information (RFI) is to conduct market research to identify organizations with capabilities in artificial intelligence (AI) for application in the discovery and advancement of broad-spectrum, small-molecule therapeutics targeting filoviruses (e.g., Ebola virus (EBOV), Sudan virus (SUDV), Marburg virus (MARV)).
This RFI seeks information regarding technical capabilities, infrastructure, relevant experience, and recommended approaches for the application of AI and advanced computational methodologies across the therapeutic development lifecycle. Areas of interest include AI-driven therapeutic design and optimization, in vitro validation of candidate hits, and early preclinical proof-of-concept evaluation.
Responding to this opportunity requires membership in the Rapid Response Partnership Vehicle (RRPV). This Consortium releases numerous solicitations throughout the year, so even if this opportunity may not end up being right for you, we strongly encourage you to join, so you are ready for the next opportunity.
Complete the form below and a program representative will reach out to you shortly to support you through the process.